2022
New Therapeutics in Alzheimer’s Disease Longitudinal Cohort study (NTAD): study protocol
Lanskey J, Kocagoncu E, Quinn A, Cheng Y, Karadag M, Pitt J, Lowe S, Perkinton M, Raymont V, Singh K, Woolrich M, Nobre A, Henson R, Rowe J. New Therapeutics in Alzheimer’s Disease Longitudinal Cohort study (NTAD): study protocol. BMJ Open 2022, 12: e055135. PMID: 36521898, PMCID: PMC9756184, DOI: 10.1136/bmjopen-2021-055135.Peer-Reviewed Original ResearchConceptsMild cognitive impairmentEarly-stage Alzheimer's diseaseCognitive impairmentPeer-reviewed scientific journalsLongitudinal cohort studyResearch Ethics CommitteeAlzheimer's diseaseAmyloid-positive mild cognitive impairmentAlzheimer's disease studyConference presentationsCohort studyMeasures of diseaseCognitive AssessmentDisease StudyStudy protocolPrimary analysisEthics CommitteeLongitudinal changesParticipantsCognitive changesWebsite publicationClinical trial durationNew therapeuticsEast of England-Cambridge Central Research Ethics CommitteeProgression of Alzheimer's disease
2021
Alpha power is associated with hippocampal volume in Alzheimer’s disease: A combined MEG and MRI study
Pitt J, Quinn A, Kocagoncu E, Karadag‐Assem M, Lanskey J, Klimovich‐Gray A, Cheng Y, Raymont V, Rowe J, Nobre A, Woolrich M. Alpha power is associated with hippocampal volume in Alzheimer’s disease: A combined MEG and MRI study. Alzheimer's & Dementia 2021, 17 DOI: 10.1002/alz.052308.Peer-Reviewed Original ResearchMild cognitive impairmentAssociated with MMSE scoreHippocampal volumeAlpha frequencyEyes closed conditionsCognitive impairmentAlpha peak frequencyAssociated with hippocampal volumeClinical benefitDementia researchAlzheimer's diseaseAmyloid-positive mild cognitive impairmentHealthy controlsIncreasing cognitive impairmentClinical trialsProgressive atrophyMulti-centreMMSE scorePatientsStage of mild cognitive impairmentCalculate hippocampal volumeMRI studiesAlpha rhythmNew therapeuticsAD patients